Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA: 603707)
China
· Delayed Price · Currency is CNY 15.09
+0.54 (3.71%)
Oct 8, 2024, 3:00 PM CST
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 3,762 | 3,923 | 3,708 | 3,681 | 2,911 | 2,467 | Upgrade
|
| Other Revenue | 8.14 | 8.65 | 4.61 | 5.25 | 3.55 | 2.37 | Upgrade
|
| Revenue | 3,770 | 3,931 | 3,713 | 3,687 | 2,915 | 2,470 | Upgrade
|
| Revenue Growth (YoY) | -6.70% | 5.89% | 0.71% | 26.48% | 18.03% | 45.25% | Upgrade
|
| Cost of Revenue | 3,396 | 3,272 | 1,778 | 1,603 | 1,236 | 1,204 | Upgrade
|
| Gross Profit | 374.76 | 659.14 | 1,935 | 2,083 | 1,679 | 1,265 | Upgrade
|
| Selling, General & Admin | 464.69 | 566.47 | 617.61 | 606.05 | 550.1 | 419.3 | Upgrade
|
| Research & Development | 395.82 | 372.29 | 263.66 | 220.95 | 187.53 | 166.35 | Upgrade
|
| Other Operating Expenses | 42.44 | 55.73 | 30.98 | 22.15 | 4.92 | 4.12 | Upgrade
|
| Operating Expenses | 905.33 | 991.45 | 913 | 851.58 | 751.05 | 592.94 | Upgrade
|
| Operating Income | -530.58 | -332.31 | 1,022 | 1,232 | 927.95 | 672.4 | Upgrade
|
| Interest Expense | -83.56 | -81.05 | -57.85 | -92.22 | -57.57 | -22.09 | Upgrade
|
| Interest & Investment Income | 23.07 | 27.98 | 60.74 | 27.53 | 11.64 | 14.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 35.56 | 128.88 | 154.77 | 9.37 | 1.66 | 3.69 | Upgrade
|
| Other Non Operating Income (Expenses) | -18.58 | -1.35 | -0.65 | -2.74 | -7.04 | -0.75 | Upgrade
|
| EBT Excluding Unusual Items | -574.09 | -257.84 | 1,179 | 1,174 | 876.65 | 667.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | -98.19 | -91.74 | -5.06 | 9.09 | 0.4 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.08 | -0.07 | -0.11 | -1.03 | -0.22 | 0.13 | Upgrade
|
| Other Unusual Items | 98.92 | 54.89 | 12.02 | 21.98 | 37.8 | 12.87 | Upgrade
|
| Pretax Income | -573.44 | -294.76 | 1,185 | 1,204 | 914.63 | 680.37 | Upgrade
|
| Income Tax Expense | -164.49 | -105.31 | 98.85 | 139.84 | 117.98 | 74.12 | Upgrade
|
| Earnings From Continuing Operations | -408.95 | -189.45 | 1,087 | 1,064 | 796.65 | 606.24 | Upgrade
|
| Minority Interest in Earnings | 0.02 | 0 | 4.31 | -4.62 | 9.47 | -1.28 | Upgrade
|
| Net Income | -408.93 | -189.45 | 1,091 | 1,059 | 806.12 | 604.96 | Upgrade
|
| Net Income to Common | -408.93 | -189.45 | 1,091 | 1,059 | 806.12 | 604.96 | Upgrade
|
| Net Income Growth | - | - | 2.98% | 31.41% | 33.25% | 42.50% | Upgrade
|
| Shares Outstanding (Basic) | 1,588 | 1,579 | 1,628 | 1,581 | 1,588 | 1,573 | Upgrade
|
| Shares Outstanding (Diluted) | 1,588 | 1,579 | 1,628 | 1,581 | 1,588 | 1,573 | Upgrade
|
| Shares Change (YoY) | -3.27% | -3.03% | 2.98% | -0.43% | 0.94% | -0.52% | Upgrade
|
| EPS (Basic) | -0.26 | -0.12 | 0.67 | 0.67 | 0.51 | 0.38 | Upgrade
|
| EPS (Diluted) | -0.26 | -0.12 | 0.67 | 0.67 | 0.51 | 0.38 | Upgrade
|
| EPS Growth | - | - | 0% | 31.97% | 32.01% | 43.24% | Upgrade
|
| Free Cash Flow | 990.64 | 1,200 | 125.37 | 242.87 | -860.21 | -956.79 | Upgrade
|
| Free Cash Flow Per Share | 0.62 | 0.76 | 0.08 | 0.15 | -0.54 | -0.61 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.115 | 0.115 | 0.089 | 0.137 | Upgrade
|
| Dividend Growth | -13.04% | -13.04% | -0.35% | 29.95% | -34.95% | 160.00% | Upgrade
|
| Gross Margin | 9.94% | 16.77% | 52.10% | 56.51% | 57.60% | 51.24% | Upgrade
|
| Operating Margin | -14.07% | -8.45% | 27.51% | 33.41% | 31.84% | 27.23% | Upgrade
|
| Profit Margin | -10.85% | -4.82% | 29.38% | 28.73% | 27.66% | 24.50% | Upgrade
|
| Free Cash Flow Margin | 26.27% | 30.53% | 3.38% | 6.59% | -29.51% | -38.74% | Upgrade
|
| EBITDA | -368.32 | -180.87 | 1,161 | 1,325 | 1,013 | 717.39 | Upgrade
|
| EBITDA Margin | -9.77% | -4.60% | 31.27% | 35.94% | 34.74% | 29.05% | Upgrade
|
| D&A For EBITDA | 162.26 | 151.44 | 139.53 | 93.22 | 84.55 | 44.99 | Upgrade
|
| EBIT | -530.58 | -332.31 | 1,022 | 1,232 | 927.95 | 672.4 | Upgrade
|
| EBIT Margin | -14.07% | -8.45% | 27.51% | 33.41% | 31.84% | 27.23% | Upgrade
|
| Effective Tax Rate | - | - | 8.34% | 11.62% | 12.90% | 10.89% | Upgrade
|
| Revenue as Reported | 3,770 | 3,931 | 3,713 | 3,687 | 2,915 | 2,470 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.